We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The German Federal Patent Court requested that the Court of Justice of the European Union (the Court) provide a ruling as to whether a Supplementary Protection Certificate (SPC) may be granted if it would not result in a “positive” term, because marketing authorization (APM) for a drug had been obtained within five years of the filing of the corresponding patent application
